Our SMDC technology and companion imaging agents have the potential for broad application for a number of diseases. Cancers that express the folate receptor, such as ovarian, non-small cell lung (NSCLC), breast, colorectal, renal cell, and gastric, affect more than 1 million people in the US, Japan, and Europe.1
Folate is required for cellular division, and rapidly dividing cancer cells express receptors for the vitamin. We hope to improve treatment for these patients by using a drug attached to a folate ligand that can be delivered directly to the folate receptors on the cancer cells. Endocyte is developing other targeting ligands beyond folate, such as, prostate-specific membrane antigen (PSMA) that may benefit additional cancer patients.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.
1. American Cancer Society and Endocyte estimates based upon imaging studies and tissue biopsies.